A Phase 2 study of intra-articular injection of DE-098 in patients with rheumatoid arthritis
Phase 2
- Conditions
- Rheumatoid arthritis
- Registration Number
- JPRN-jRCT2080221430
- Lead Sponsor
- Santen Pharmaceutical Co., Ltd.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Patients diagnosed with rheumatoid arthritis
Exclusion Criteria
Participating in other clinical trials
In pregnancy or breast-feeding
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Efficacy and safety assessment<br>Assessment of the target joint, adverse events (AE) and adverse drug reactions (ADR)
- Secondary Outcome Measures
Name Time Method